In our previous report we were able to demonstrate that ara-C-treated patients with higher SAMHD1 mRNA expression at diagnosis had reduced OS and event-free survival (EFS) as compared to patients with lower SAMHD1 expression, in both the adult de novo The Cancer Genome Atlas (TCGA) and the pediatric Therapeutically Applicable Research to Generate Effective Treatments (TARGET) AML cohorts7. This evidence concerns the gene SAMHD1 and acute myeloid leukemia.